{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T14:27:51Z","timestamp":1791556071193,"version":"4.3.4"},"reference-count":71,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Spanish Ministry of Economy and Competiveness","award":["PI1100325"],"award-info":[{"award-number":["PI1100325"]}]},{"name":"Madrid Regional Government","award":["S2017\/BMD-3740"],"award-info":[{"award-number":["S2017\/BMD-3740"]}]},{"DOI":"10.13039\/100011941","name":"Government of the Principality of Asturias","doi-asserted-by":"publisher","award":["PCTI-2021\u20132023 IDI\/2021\/111"],"award-info":[{"award-number":["PCTI-2021\u20132023 IDI\/2021\/111"]}],"id":[{"id":"10.13039\/100011941","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"ERDF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Department of Economy, Knowledge, Business","award":["FEDER-UCA18-106933"],"award-info":[{"award-number":["FEDER-UCA18-106933"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The clinical debut of schizophrenia is frequently a first episode of psychosis (FEP). As such, there is considerable interest in identifying associations between biological markers and clinical or cognitive characteristics that help predict the progression and outcome of FEP patients. Previous studies showed that high prolactin, low oxytocin, and high homocysteine are factors associated with FEP 6 months after diagnosis, at which point plasma levels were correlated with some clinical and cognitive characteristics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We reexamined 75 patients at 12 months after diagnosis to measure the evolution of these molecules and assess their association with clinical features.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At follow-up, FEP patients had lower prolactin levels than at baseline, and patients treated with risperidone or paliperidone had higher prolactin levels than patients who received other antipsychotic agents. By contrast, no changes in oxytocin and homocysteine plasma levels were observed between the baseline and follow-up. In terms of clinical features, we found that plasma prolactin and homocysteine levels were correlated with the severity of the psychotic symptoms in male FEP patients, suggesting that they might be factors associated with psychotic symptomatology but only in men. Together with oxytocin, these molecules may also be related to sustained attention, verbal ability, and working memory cognitive domains in FEP patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This study suggests that focusing on prolactin, oxytocin, and homocysteine at a FEP may help select adequate pharmacological treatments and develop new tools to improve the outcome of these patients, where sex should also be borne in mind.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ijnp\/pyad051","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T15:47:41Z","timestamp":1692632861000},"page":"796-807","source":"Crossref","is-referenced-by-count":7,"title":["Association of Prolactin, Oxytocin, and Homocysteine With the Clinical and Cognitive Features of a First Episode of Psychosis Over a 1-Year Follow-Up"],"prefix":"10.1093","volume":"26","author":[{"given":"Maria","family":"Hidalgo-Figueroa","sequence":"first","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Salud Mental (CIBERSAM), ISCIII , Madrid , Spain"},{"name":"Biomedical Research and Innovation Institute of Cadiz (INiBICA), Research Unit, Puerta del Mar University Hospital , C\u00e1diz , Spain"},{"name":"Neuropsychopharmacology and Psychobiology Research Group, Psychobiology Area, Department of Psychology, Universidad de C\u00e1diz , Puerto Real (C\u00e1diz ), Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Salazar","sequence":"additional","affiliation":[{"name":"Biomedical Research and Innovation Institute of Cadiz (INiBICA), Research Unit, Puerta del Mar University Hospital , C\u00e1diz , Spain"},{"name":"Department of Statistics and Operational Research, University of C\u00e1diz , Puerto Real (C\u00e1diz ), Spain"},{"name":"The Observatory of Pain, University of C\u00e1diz , C\u00e1diz , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Romero-L\u00f3pez-Alberca","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Salud Mental (CIBERSAM), ISCIII , Madrid , Spain"},{"name":"Biomedical Research and Innovation Institute of Cadiz (INiBICA), Research Unit, Puerta del Mar University Hospital , C\u00e1diz , Spain"},{"name":"Personality, Evaluation and Psychological Treatment Area, Department of Psychology, Universidad de C\u00e1diz , Puerto Real (C\u00e1diz ), Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina S","family":"MacDowell","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Salud Mental (CIBERSAM), ISCIII , Madrid , Spain"},{"name":"Departamento de Farmacolog\u00eda y Toxicolog\u00eda, Facultad de Medicina, Univ. Complutense de Madrid, Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (i+12), IUINQ , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja","family":"Garc\u00eda-Bueno","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Salud Mental (CIBERSAM), ISCIII , Madrid , Spain"},{"name":"Departamento de Farmacolog\u00eda y Toxicolog\u00eda, Facultad de Medicina, Univ. Complutense de Madrid, Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (i+12), IUINQ , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6887-7149","authenticated-orcid":false,"given":"Miquel","family":"Bioque","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Salud Mental (CIBERSAM), ISCIII , Madrid , Spain"},{"name":"Institut d\u2019investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPs), Barcelona Cl\u00ednic Schizophrenia Unit (BCSU), Neuroscience Institute, Hospital Cl\u00ednic de Barcelona, Department of Medicine, University of Barcelona , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8748-6717","authenticated-orcid":false,"given":"Miquel","family":"Bernardo","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Salud Mental (CIBERSAM), ISCIII , Madrid , Spain"},{"name":"Institut d\u2019investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPs), Barcelona Cl\u00ednic Schizophrenia Unit (BCSU), Neuroscience Institute, Hospital Cl\u00ednic de Barcelona, Department of Medicine, University of Barcelona , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Parellada","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Salud Mental (CIBERSAM), ISCIII , Madrid , Spain"},{"name":"Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, IiSGM, School of Medicine, Universidad Complutense , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Gonz\u00e1lez-Pinto","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Salud Mental (CIBERSAM), ISCIII , Madrid , Spain"},{"name":"Department of Psychiatry, Hospital Universitario de Alava, BIOARABA, EHU , Vitoria-Gasteiz , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Paz","family":"Garc\u00eda-Portilla","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Universidad de Oviedo, Instituto de Investigaci\u00f3n Sanitaria del Principado de Asturias (ISPA), Instituto de Neurociencias del Principado de Asturias (INEUROPA), Servicio de Salud del Principado de Asturias (SESPA) , Oviedo , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Lobo","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Salud Mental (CIBERSAM), ISCIII , Madrid , Spain"},{"name":"Department of Medicine and Psychiatry, Universidad de Zaragoza, Instituto de Investigaci\u00f3n Sanitaria Arag\u00f3n (IIS Arag\u00f3n) , Zaragoza , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Rodriguez-Jimenez","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Salud Mental (CIBERSAM), ISCIII , Madrid , Spain"},{"name":"Department of Psychiatry, Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (imas12)\/Universidad Complutense de Madrid (UCM) , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Berrocoso","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Salud Mental (CIBERSAM), ISCIII , Madrid , Spain"},{"name":"Biomedical Research and Innovation Institute of Cadiz (INiBICA), Research Unit, Puerta del Mar University Hospital , C\u00e1diz , Spain"},{"name":"Neuropsychopharmacology and Psychobiology Research Group, Psychobiology Area, Department of Psychology, Universidad de C\u00e1diz , Puerto Real (C\u00e1diz ), Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan C","family":"Leza","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Salud Mental (CIBERSAM), ISCIII , Madrid , Spain"},{"name":"Departamento de Farmacolog\u00eda y Toxicolog\u00eda, Facultad de Medicina, Univ. Complutense de Madrid, Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (i+12), IUINQ , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"FLAMM-PEPs study","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"CIBERSAM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,21]]},"reference":[{"key":"2023112505441425900_CIT0001","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/schbul\/sby143","article-title":"Longitudinal cognitive performance in individuals at ultrahigh risk for psychosis: a 10-year follow-up","volume":"45","author":"Allott","year":"2019","journal-title":"Schizophr Bull"},{"key":"2023112505441425900_CIT0002","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.schres.2012.05.007","article-title":"Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies","volume":"139","author":"Alvarez-Jimenez","year":"2012","journal-title":"Schizophr Res"},{"key":"2023112505441425900_CIT0003","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2000","edition":"4"},{"key":"2023112505441425900_CIT0004","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF02245617","article-title":"Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial","volume":"124","author":"Beasley","year":"1996","journal-title":"Psychopharmacology"},{"key":"2023112505441425900_CIT0005","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0306-4530(85)90056-3","article-title":"Vasopressin-oxytocin in cerebrospinal fluid of schizophrenic patients and normal controls","volume":"10","author":"Beckmann","year":"1985","journal-title":"Psychoneuroendocrinology"},{"key":"2023112505441425900_CIT0006","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.rpsm.2012.11.001","article-title":"Assessing clinical and functional outcomes in a gene\u2013environment interaction study in first episode of psychosis (PEPs)","volume":"6","author":"Bernardo","year":"2013","journal-title":"Rev Psiquiatr Salud Ment (Eng Ed)"},{"key":"2023112505441425900_CIT0007","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1177\/0269881109106914","article-title":"A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia","volume":"24","author":"Berwaerts","year":"2010","journal-title":"J Psychopharmacol"},{"key":"2023112505441425900_CIT0008","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.neubiorev.2017.05.007","article-title":"Oxytocin effects in schizophrenia: reconciling mixed findings and moving forward","volume":"80","author":"Bradley","year":"2017","journal-title":"Neurosci Biobehav Rev"},{"key":"2023112505441425900_CIT0009","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/schbul\/sbu094","article-title":"A double-blind randomized controlled trial of oxytocin nasal spray and social cognition training for young people with early psychosis","volume":"41","author":"Cacciotti-Saija","year":"2015","journal-title":"Schizophr Bull"},{"key":"2023112505441425900_CIT0010","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/acps.13222","article-title":"Decreased oxytocin plasma levels and oxytocin receptor expression in borderline personality disorder","volume":"142","author":"Carrasco","year":"2020","journal-title":"Acta Psychiatr Scand"},{"key":"2023112505441425900_CIT0011","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.biopsych.2008.03.020","article-title":"Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative","volume":"64","author":"Carter","year":"2008","journal-title":"Biol Psychiatry"},{"key":"2023112505441425900_CIT0012","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/HRP.0b013e3182a75b7d","article-title":"The role of oxytocin in psychiatric disorders: a review of biological and therapeutic research findings","volume":"21","author":"Cochran","year":"2013","journal-title":"Harv Rev Psychiatry"},{"key":"2023112505441425900_CIT0013","volume-title":"Conners\u2019 continuous performance test II (CPT II V. 5)","author":"Conners","year":"2004"},{"key":"2023112505441425900_CIT0014","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.schres.2017.01.046","article-title":"Effects of aripiprazole, quetiapine and ziprasidone on plasma prolactin levels in individuals with first episode nonaffective psychosis: analysis of a randomized open-label 1 year study","volume":"189","author":"Crespo-Facorro","year":"2017","journal-title":"Schizophr Res"},{"key":"2023112505441425900_CIT0015","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1517\/13543784.9.4.819","article-title":"Ziprasidone: comprehensive overview and clinical use of a novel antipsychotic","volume":"9","author":"Daniel","year":"2000","journal-title":"Expert Opin Investig Drugs"},{"key":"2023112505441425900_CIT0016","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00737-018-0899-x","article-title":"Plasma prolactin levels are associated with the severity of illness in drug-naive first-episode psychosis female patients","volume":"22","author":"Delgado-Alvarado","year":"2019","journal-title":"Arch Womens Ment Health"},{"key":"2023112505441425900_CIT0017","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/archpsyc.1976.01770060086012","article-title":"The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance","volume":"33","author":"Endicott","year":"1976","journal-title":"Arch Gen Psychiatry"},{"key":"2023112505441425900_CIT0018","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.neulet.2017.04.025","article-title":"Effect of risperidone on serum homocysteine levels in first-episode, drug-na\u00efve patients with schizophrenia","volume":"650","author":"Fan","year":"2017","journal-title":"Neurosci Lett"},{"key":"2023112505441425900_CIT0019","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/0004867416641195","article-title":"Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders","volume":"50","author":"Galletly","year":"2016","journal-title":"Aust N Z J Psychiatry"},{"key":"2023112505441425900_CIT0020","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/schbul\/sbt001","article-title":"Pro-\/anti-inflammatory dysregulation in patients with first episode of psychosis: toward an integrative inflammatory hypothesis of schizophrenia","volume":"40","author":"Garc\u00eda-Bueno","year":"2014","journal-title":"Schizophr Bull"},{"key":"2023112505441425900_CIT0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ijnp\/pyu037","article-title":"Pro-\/antiinflammatory dysregulation in early psychosis: results from a 1-year follow-Up study","volume":"18","author":"Garcia-Bueno","year":"2015","journal-title":"Int J Neuropsychopharmacol"},{"key":"2023112505441425900_CIT0022","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.schres.2011.07.025","article-title":"Prolactin concentrations in newly diagnosed, antipsychotic-na\u00efve patients with nonaffective psychosis","volume":"134","author":"Garcia-Rizo","year":"2012","journal-title":"Schizophr Res"},{"key":"2023112505441425900_CIT0023","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","article-title":"International consensus study of antipsychotic dosing","volume":"167","author":"Gardner","year":"2010","journal-title":"Am J Psychiatry"},{"key":"2023112505441425900_CIT0024","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0920-9964(94)90021-3","article-title":"Cerebrospinal fluid oxytocin concentration in schizophrenic patients does not differ from control subjects and is not changed by neuroleptic medication","volume":"11","author":"Glovinsky","year":"1994","journal-title":"Schizophr Res"},{"key":"2023112505441425900_CIT0025","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.schres.2007.09.019","article-title":"Diminished plasma oxytocin in schizophrenic patients with neuroendocrine dysfunction and emotional deficits","volume":"98","author":"Goldman","year":"2008","journal-title":"Schizophr Res"},{"key":"2023112505441425900_CIT0026","first-page":"156","article-title":"Prolactin concentrations in antipsychotic-na\u00efve patients with schizophrenia and related disorders: a meta-analysis","volume-title":"Schizophr Res","author":"Gonz\u00e1lez-Blanco","year":"2016"},{"key":"2023112505441425900_CIT0027","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.biopsych.2004.06.023","article-title":"Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria","volume":"56","author":"Green","year":"2004","journal-title":"Biol Psychiatry"},{"key":"2023112505441425900_CIT0028","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0306-4530(02)00112-9","article-title":"Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects","volume":"28","author":"Halbreich","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"2023112505441425900_CIT0029","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/ijnp\/pyac023","article-title":"The influence of oxytocin and prolactin during a first episode of psychosis: the implication of sex differences, clinical features, and cognitive performance","volume":"25","author":"Hidalgo-Figueroa","year":"2022","journal-title":"Int J Neuropsychopharmacol"},{"key":"2023112505441425900_CIT0030","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/jnr.10416","article-title":"Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage","volume":"70","author":"Ho","year":"2002","journal-title":"J Neurosci Res"},{"key":"2023112505441425900_CIT0031","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/BF00429215","article-title":"Clozapine: plasma levels and prolactin response","volume":"73","author":"Kane","year":"1981","journal-title":"Psychopharmacology"},{"key":"2023112505441425900_CIT0032","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00429-019-01989-4","article-title":"Electrophysiology and distribution of oxytocin and vasopressin neurons in the hypothalamic paraventricular nucleus: a study in male and female rats","volume":"225","author":"Kania","year":"2020","journal-title":"Brain Struct Funct"},{"key":"2023112505441425900_CIT0033","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/00004583-199707000-00021","article-title":"Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data","volume":"36","author":"Kaufman","year":"1997","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"2023112505441425900_CIT0034","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"2023112505441425900_CIT0035","doi-asserted-by":"crossref","first-page":"463","DOI":"10.31887\/DCNS.2015.17.4\/pkirsch","article-title":"Oxytocin in the socioemotional brain: implications for psychiatric disorders","volume":"17","author":"Kirsch","year":"2015","journal-title":"Dialogues Clin Neurosci"},{"key":"2023112505441425900_CIT0036","doi-asserted-by":"crossref","first-page":"6920","DOI":"10.1523\/JNEUROSCI.20-18-06920.2000","article-title":"Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity","volume":"20","year":"2000","journal-title":"J Neurosci"},{"key":"2023112505441425900_CIT0037","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.psyneuen.2018.11.028","article-title":"The role of cortisol and prolactin in the pathogenesis and clinical expression of psychotic disorders","volume":"102","author":"Labad","year":"2019","journal-title":"Psychoneuroendocrinology"},{"key":"2023112505441425900_CIT0038","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s004060070005","article-title":"The genetic epidemiology of schizophrenia and of schizophrenia spectrum disorders","volume":"250","author":"Lichtermann","year":"2000","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"2023112505441425900_CIT0039","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.3390\/biomedicines10112741","article-title":"Homocysteine, cognitive functions, and degenerative dementias: state of the art","volume":"10","author":"Luzzi","year":"2022","journal-title":"Biomedicines"},{"key":"2023112505441425900_CIT0040","doi-asserted-by":"crossref","first-page":"e89428","DOI":"10.1371\/journal.pone.0089428","article-title":"Increased prolactin levels are associated with impaired processing speed in subjects with early psychosis","volume":"9","author":"Montalvo","year":"2014","journal-title":"PLoS One"},{"key":"2023112505441425900_CIT0041","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1177\/0004867417744254","article-title":"Sex differences in the relationship between prolactin levels and impaired processing speed in early psychosis","volume":"52","author":"Montalvo","year":"2018","journal-title":"Aust N Z J Psychiatry"},{"key":"2023112505441425900_CIT0042","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.mp.4001746","article-title":"Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis","volume":"11","author":"Muntjewerff","year":"2006","journal-title":"Mol Psychiatry"},{"key":"2023112505441425900_CIT0043","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4161\/chan.28946","article-title":"Prolactin receptor in regulation of neuronal excitability and channels","volume":"8","author":"Patil","year":"2014","journal-title":"Channels"},{"key":"2023112505441425900_CIT0044","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archpsyc.64.1.19","article-title":"Lifetime prevalence of psychotic and bipolar I disorders in a general population","volume":"64","author":"Per\u00e4l\u00e4","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"2023112505441425900_CIT0045","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0165-1781(94)90093-0","article-title":"Psychometric properties of the Positive and Negative Syndrome Scale (PANSS) in schizophrenia","volume":"53","author":"Peralta","year":"1994","journal-title":"Psychiatry Res"},{"key":"2023112505441425900_CIT0046","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fpsyt.2021.643112","article-title":"Prospective long-term cohort study of subjects with first-episode psychosis examining eight major outcome domains and their predictors: study protocol","volume":"12","author":"Peralta","year":"2021","journal-title":"Front Psychiatry"},{"key":"2023112505441425900_CIT0047","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/13651501.2016.1197274","article-title":"Prolactin levels in drug-na\u00efve patients with schizophrenia and other psychotic disorders","volume":"20","author":"Petrikis","year":"2016","journal-title":"Int J Psychiatry Clin Pract"},{"key":"2023112505441425900_CIT0048","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/j.pnpbp.2008.09.009","article-title":"Plasma homocysteine levels in young male patients in the exacerbation and remission phase of schizophrenia","volume":"32","author":"Petronijevi\u0107","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2023112505441425900_CIT0049","first-page":"421","article-title":"The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review","volume":"28","author":"Peuskens","year":"2014","journal-title":"CNS Drugs"},{"key":"2023112505441425900_CIT0050","first-page":"S148","article-title":"Hyperprolactinemia - side effect or part of the illness","volume":"31","author":"Pisk","year":"2019","journal-title":"Psychiatr Danub"},{"key":"2023112505441425900_CIT0051","volume-title":"The Halstead-Reitan neuropsychological test battery: theory and clinical interpretation","author":"Reitan","year":"1993"},{"key":"2023112505441425900_CIT0052","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1017\/S0033291713000226","article-title":"Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis","volume":"43","author":"Riecher-R\u00f6ssler","year":"2013","journal-title":"Psychol Med"},{"key":"2023112505441425900_CIT0053","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.schres.2013.01.019","article-title":"Peripheral vasopressin but not oxytocin relates to severity of acute psychosis in women with acutely-ill untreated first-episode psychosis","volume":"146","author":"Rubin","year":"2013","journal-title":"Schizophr Res"},{"key":"2023112505441425900_CIT0054","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.schres.2010.09.014","article-title":"Peripheral oxytocin is associated with reduced symptom severity in schizophrenia","volume":"124","author":"Rubin","year":"2010","journal-title":"Schizophr Res"},{"key":"2023112505441425900_CIT0055","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.schres.2011.06.002","article-title":"Sex-specific associations between peripheral oxytocin and emotion perception in schizophrenia","volume":"130","author":"Rubin","year":"2011","journal-title":"Schizophr Res"},{"key":"2023112505441425900_CIT0056","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.psychres.2016.04.117","article-title":"Peripheral oxytocin and vasopressin: biomarkers of psychiatric disorders? A comprehensive systematic review and preliminary meta-analysis","volume":"241","author":"Rutigliano","year":"2016","journal-title":"Psychiatry Res"},{"key":"2023112505441425900_CIT0057","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.schres.2012.06.016","article-title":"Negative correlation between cerebrospinal fluid oxytocin levels and negative symptoms of male patients with schizophrenia","volume":"139","author":"Sasayama","year":"2012","journal-title":"Schizophr Res"},{"key":"2023112505441425900_CIT0058","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/archpsyc.1983.01790100074010","article-title":"A children\u2019s global assessment scale (CGAS)","volume":"40","author":"Shaffer","year":"1983","journal-title":"Arch Gen Psychiatry"},{"key":"2023112505441425900_CIT0059","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s40263-016-0315-x","article-title":"Potential of oxytocin in the treatment of schizophrenia","volume":"30","author":"Shilling","year":"2016","journal-title":"CNS Drugs"},{"key":"2023112505441425900_CIT0060","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/schbul\/sbac152","article-title":"Antipsychotic use and risk of low-energy fractures in people with schizophrenia: a nationwide nested case-control study in Finland","volume":"49","author":"Solmi","year":"2022","journal-title":"Schizophr Bull"},{"key":"2023112505441425900_CIT0061","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11920-019-1091-3","article-title":"Non-genetic factors in schizophrenia","volume":"21","author":"Stilo","year":"2019","journal-title":"Curr Psychiatry Rep"},{"key":"2023112505441425900_CIT0062","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jpsychires.2019.02.017","article-title":"Endogenous oxytocin levels are associated with impaired social cognition and neurocognition in schizophrenia","volume":"112","author":"Strauss","year":"2019","journal-title":"J Psychiatr Res"},{"key":"2023112505441425900_CIT0063","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jpsychires.2020.06.014","article-title":"Relation between self-perceived stress, psychopathological symptoms and the stress hormone prolactin in emerging psychosis","volume":"136","author":"Studerus","year":"2021","journal-title":"J Psychiatr Res"},{"key":"2023112505441425900_CIT0064","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/PSY.0b013e31821df0c2","article-title":"Evaluation of enzyme immunoassay and radioimmunoassay methods for the measurement of plasma oxytocin","volume":"73","author":"Szeto","year":"2011","journal-title":"Psychosom Med"},{"key":"2023112505441425900_CIT0065","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S2215-0366(21)00241-8","article-title":"Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland","volume":"8","author":"Taipale","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"2023112505441425900_CIT0066","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1192\/apt.bp.115.014977","article-title":"Hyperprolactinaemia: a guide for psychiatrists","volume":"23","author":"Wadoo","year":"2017","journal-title":"BJPsych Adv"},{"key":"2023112505441425900_CIT0067","article-title":"Wechsler adult intelligence scale","volume-title":"Arch Clin Neuropsychol","author":"Wechsler","year":"1955"},{"key":"2023112505441425900_CIT0068","volume-title":"Wechsler intelligence scale for children\u2013Fourth Edition (WISC-IV)","author":"Wechsler","year":"2003"},{"key":"2023112505441425900_CIT0069","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.psyneuen.2016.10.013","article-title":"Effects of intranasal oxytocin on symptoms of schizophrenia: a multivariate Bayesian meta-analysis","volume":"75","author":"Williams","year":"2017","journal-title":"Psychoneuroendocrinology"},{"key":"2023112505441425900_CIT0070","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3390\/antiox12010202","article-title":"Potential antioxidative activity of homocysteine in erythrocytes under oxidative stress","volume":"12","author":"Ye","year":"2023","journal-title":"Antioxidants"},{"key":"2023112505441425900_CIT0071","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.schres.2018.12.007","article-title":"Adjunctive intranasal oxytocin for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials","volume":"206","author":"Zheng","year":"2019","journal-title":"Schizophr Res"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyad051\/52824182\/pyad051.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/26\/11\/796\/53799854\/pyad051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/26\/11\/796\/53799854\/pyad051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T05:45:13Z","timestamp":1700891113000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/26\/11\/796\/7246690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,21]]},"references-count":71,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,8,21]]},"published-print":{"date-parts":[[2023,11,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyad051","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,1]]},"published":{"date-parts":[[2023,8,21]]}}}